Asher Bio is transforming the power of immunotherapy with new medicines designed to selectively activate only the immune cell types that promote a beneficial therapeutic effect, while simultaneously avoiding the opposing, antagonistic, and toxic effects driven by other immune cell types. We utilize a unique technology platform called cis-targeting that can be systematically applied to target a variety of immunomodulators to a range of different immune cell types. Our lead program is AB248, a cis-targeted IL-2 immunotherapy. AB248 has shown superior anti-tumor activity in preclinical models compared to other IL-2 therapies currently available and in clinical development. As a potential best-in-class IL-2, we are developing AB248 for the treatment of solid tumors. Beyond AB248, Asher Bio is applying our cis-targeting discovery platform to develop additional immunotherapies for the treatment of cancer, autoimmune disease, and infectious disease.
Privately Funded Company
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):